SBIR-STTR Award

Quantifying Dimerization of Receptor Tyrosine Kinase by Quantum Dot Fret Immunoassay in Tissue Sections
Award last edited on: 3/4/19

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$225,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Andrew Y Wang

Company Information

Ocean Nanotech LLC (AKA: Ocean Nano Tech LLC)

7964 Arjons Drive Suite G
San Diego, CA 92126
   (858) 689-8808
   info@oceannanotech.com
   www.oceannanotech.com
Location: Single
Congr. District: 51
County: San Diego

Phase I

Contract Number: 1R43CA233382-01
Start Date: 7/3/18    Completed: 6/30/19
Phase I year
2018
Phase I Amount
$225,000
Summary This proposal is to develop a novel slide-based proximity assay platform to quantify the dimerization of receptor tyrosine kinases (RTK) in tissue. Quantification of alteration of RTK dimerization upon biological stimuli or antagonist is critical to evaluate anti-cancer therapies which aim to block RTK mediated growth signaling pathway. However, there are limited methods for quantification of protein dimerization in tissue samples. Recently, we have discovered that dual emission quantum dots can be used for Fluorescence Resonance Energy Transfer (FRET) assays, in which one emission peak without FRET serves as an internal standard and the other serves as FRET emission to interact with acceptor dye. In this proposal, we will use EGFR targeted therapies in squamous cell carcinoma of the head and neck as a model system to demonstrate the feasibility of using QD-FRET for quantifying protein dimerization on tissues. Three specific aims are proposed in Phase I study: Aim 1- Prepare QD-Ab conjugates with desired affinity and specificity; Aim 2 - Develop quantification method for the QD-FRET assay; Aim 3 - Validate QD-FRET assay in human SCCHN cell lines and xenograft tissues. Completion of this Phase I project will greatly facilitate further development of the QD-FRET technology for both research and clinical settings.

Project Terms:
Affinity; Antibodies; Antibody Affinity; antibody conjugate; Antibody Specificity; assay development; base; Biological; Biological Assay; Biological Models; Biological Process; biomarker evaluation; Biophysics; Blood specimen; Camels; cancer cell; Cancer cell line; cancer therapy; Cell Line; Cells; Chemistry; Clinical; clinical application; computerized data processing; Cultured Cells; Data Collection; design; Development; dimer; Dimerization; DNA; drug discovery; Drug Targeting; Dyes; Epidermal Growth Factor Receptor; Epitopes; ERBB2 gene; ERBB3 gene; Family; Family member; Fluorescence; fluorescence microscope; Fluorescence Resonance Energy Transfer; Formalin; Growth; Head and Neck Squamous Cell Carcinoma; Heterodimerization; Homo; Human; Human Resources; Immunoassay; Immunoprecipitation; improved; In Situ; instrument; internal control; Ligation; Link; Mediating; Methods; microscopic imaging; Molecular Analysis; Molecular Biology; molecular dynamics; Monitor; Noise; novel; operation; Paraffin Embedding; Patients; Phase; phase 1 study; Play; Protein Conformation; protein protein interaction; Proteins; Quantum Dots; Receptor Protein-Tyrosine Kinases; Research; Resistance; Role; Sampling; Signal Pathway; Signal Transduction; Slide; Specificity; Stimulus; success; targeted agent; targeted cancer therapy; targeted treatment; Technology; Technology Transfer; Testing; Tissue Sample; Tissues; Tumor Tissue; Work; Xenograft procedure;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----